Results 181 to 190 of about 5,561 (244)

Secondary type II hyperlipoproteinemia in patients with anorexia nervosa

Metabolism, 1978
In 18 patients with anorexia nervosa, plasma cholesterol and triglyceride concentral concentrations were repeatedly determined over a period of 14 mo. In 11 patients elevated cholesterol concentrations were found which were due to an increase of low-density lipoprotein cholesterol, whereas high-density lipoprotein and very low density lipoprotein ...
H. Greten, R. Mordasini, G. Klose
openaire   +3 more sources

Elevated levels of sphingolipids in type II (a+b) hyperlipoproteinemia

Thrombosis Research, 1974
Abstract The levels of sphingomyelin, neutral glycosphingolipids and gangliosides were studied in normal and type II hyperproteinemic plasmas. Sphingomyelin levels were elevated and there was an excellent correlation between cholesterol and sphingomyelin (r=0.86). The correlation between cholesterol and the remainder of the phospholipids (i.e., total
James H. Zavoral, William Krivit, Thomas B. Auran   +2 more
openaire   +2 more sources

Colestipol in familial type II hyperlipoproteinemia: A three‐year trial

Clinical Pharmacology & Therapeutics, 1976
Colestipol. a new bile acid sequestrant polymer. has been shown to lower the serum cholesterol level more than 30% in 13 patients with familial type 11 hyperlipoproteinemia. Placebo for 6 wk was followed by colestipol for periods up to 36 mo. A slight but not significant increase of serum triglyceride concentrations was observed during the first 18 mo.
C. Harvengt, Jean-Pierre Desager
openaire   +3 more sources

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

The American Journal of Cardiology, 1986
Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction.
S. S. Fojo, Jeffrey M. Hoeg, Dennis L. Sprecher, H. Bryan Brewer, Richard E. Gregg, Kent R. Bailey, Martha B. Maher, Loren A. Zech, Karl J. Lackner, Michael A. Anchors, Marina Bojanovski   +10 more
openaire   +2 more sources

Increased in vivo and in vitro platelet function in type II- and type IV-hyperlipoproteinemia

Thrombosis Research, 1979
Abstract Platelet function in vivo and in vitro was examined in 10 patients with type IIa-, 8 patients with type IIb-, and 16 patients with type IV-hyperlipidemia (HLP) and 24 control subjects closely matched for age and sex. Patients with type IIb- and IV-HLP showed significantly shorter template bleeding times in the presence of similar blood ...
Gustav Schonfeld, J. Heinrich Joist, R. Kendall Baker   +2 more
openaire   +3 more sources

Mevinolin and Neomycin in the Treatment of Type II Hyperlipoproteinemia

1987
The reduction of elevated low-density lipoprotein (LDL) cholesterol concentrations in patients with type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents that may be of value in treating hypercholesterolemia are mevinolin and neomycin.
Jeffrey M. Hoeg, S. S. Fojo, H. Bryan BrewerJr., Kent R. Bailey, Martha B. Maher   +4 more
openaire   +2 more sources

Homozygous Type II Hyperlipoproteinemia Treatment

JAMA, 1974
Dietary treatment was minimally effective in two children with homozygous type II hyperlipoproteinemia who had no evidence of atherosclerosis. Neither patient could tolerate cholestyramine resin in therapeutic doses. A partial ileal bypass operation was performed on each child, aged 10 and 8 years old.
Robert Kim, John F. Balfour
openaire   +3 more sources

Halofenate in the treatment of type II hyperlipoproteinemia Double blind comparison with clofibrate

Atherosclerosis, 1976
A double-blind study comparing halofenate, a new lipid-lowering investigation drug, with an established drug, clofibrate, was conducted on 33 clinic patients with Type II hyperlipoproteinemia for a period of 48-96 weeks. All but 10 patients had some type of symptomatic major vascular disease.
Irving F. Kanner, E. Douglas Rees, Ronald D. Hamilton, Shirley Wasson, Thomas L. Hearn   +4 more
openaire   +3 more sources

PEDIATRIC FAMILIAL TYPE II HYPERLIPOPROTEINEMIA: THERAPY WITH DIET AND CHOLESTYRAMINE RESIN

Pediatrics, 1973
Effects of a low cholesterol (<300 mg/day), polyunsaturate rich (P:S 1.5/1) diet and cholestyramine (12 gm active resin/day) were studied in 36 children with familial type II hyperlipoproteinemia. In 11 children after six months on diet alone, cholesterol and low density lipoprotein cholesterol (LDL) were reduced to normal levels.
R. Fallat, Reginald C. Tsang, C. J. Glueck   +2 more
openaire   +3 more sources

THE EFFECT OF SOYA LECITHIN ON SERUM LIPID VALUES IN TYPE II HYPERLIPOPROTEINEMIA

Acta Medica Scandinavica, 1974
Abstract. A group of 12 patients with type II hyperlipopro‐teinemia has been treated orally with a soya lecithin preparation. After an initial control period of 4 weeks 1.2 g soya lecithin was given per day. This amount was doubled after 4 months for an additional period of 4 months.
W. Dekker, A.F. Willebrands, H.F. Ter Welle, C. M. van Gent   +3 more
openaire   +3 more sources